ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

Complete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) will be...

Related Keywords

Australia ,Japan ,United States ,United Kingdom ,Belgium ,Melbourne ,Victoria ,Canada ,Switzerland ,San Francisco ,California ,Australian ,American ,Charlotte Telix ,Kyahn Williamson ,Colin Hayward ,Christian Behrenbruch ,Telix Pharmaceuticals ,Oliver Sartor Tulane Cancer Center ,American Society Of Clinical Oncology ,Linkedin ,Elshad Hasanov Md Anderson Cancer Center ,Drug Administration ,Andrei Iagaru Stanford University ,Australian Securities Exchange ,Prnewswire Telix Pharmaceuticals Limited ,Australian Therapeutic Goods Administration ,Darren Feldman Memorial Sloan Kettering Cancer Center ,Corporate Communications ,Health Canada ,American Society ,Clinical Oncology ,Cancers Symposium ,Pharmaceuticals Limited ,Telix Chief Medical Officer ,Brian Shuch ,Prostate Cancer ,Firefly Study ,Oliver Sartor ,Tulane Cancer Center ,Hashad Kulkarni ,Philip Cohen ,Initio Medical ,Renal Cell Cancer ,Andrei Iagaru ,Stanford University ,Elshad Hasanov ,Cancer Center ,Carbonic Anhydrase ,Monoclonal Antibody Girentuximab ,Advanced Clear Cell Renal Carcinoma ,Darren Feldman ,Memorial Sloan Kettering Cancer Center ,Managing Director ,Group Chief Executive ,